RxDoctor Payments DataLook up a doctor →

Julia Branch

Family · Cumming, GANPI 1033600341

Payments from drug & device makers

$101,925in general payments, 2019–2025

Across 344 payments — averaging $296.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$51K
  • Merck$24K
  • Ferring Pharmaceuticals Inc.$8K
  • Janssen Scientific Affairs, LLC$8K
  • Dendreon Pharmaceuticals LLC$7K
  • Pfizer$1K
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$19,45419%
  • Speaking & faculty fees$44,91244%
  • Travel & lodging$30,04429%
  • Food & beverage$7,4997%
  • Education$160%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,925 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$554,994
Medicare patients
154
Services billed
3,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide169$2,451,757
XtandiEnzalutamide42$583,295
NubeqaDarolutamide39$499,360
OrgovyxRelugolix62$160,912
GemtesaVibegron69$46,327
MyrbetriqMirabegron37$23,119
Estradiol17$2,192
Dutasteride39$2,069
Trimethoprim12$1,197
Tamsulosin Hcl61$755
Finasteride27$253
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$213
Tramadol Hcl18$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$50,715$2,451,757169 claims
Astellas Pharma US IncXtandi, Myrbetriq$70$606,41479 claims
BayerNubeqa$545$499,36039 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$552$207,239131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →